LAS VEGAS, Jan. 9, 2025 /PRNewswire/ -- Could this be the year your fitness goals finally stick?
Speediance, the emerging leader in smart fitness, is bringing groundbreaking technology to CES 2025, promising to revolutionize the way we approach health and wellness. At the heart of its showcase are two flagship innovations: the Gym Monster 2, an all-in-one home gym that adapts to every workout need, and the VeloNix Stationary Bike, a spin-bike-meets-bike-trainer that redefines cardio training with electric motor precision. Both are designed to make world-class training accessible anytime, anywhere, with AI-powered personalization and a focus on safety and user experience. These products are part of Speediance's vision to make home fitness accessible to everyone, enabling people to train like professionals from the comfort of their own space. But Speediance's ambition goes far beyond fitness equipment. With an eye on 2025, the company is poised to expand its product landscape into a fully integrated ecosystem that merges AI coaching, health monitoring, and lifestyle support. The aim is to create a seamless closed cycle for users: Monitoring – Analyzation – Suggestion – Action – Monitoring. By incorporating AI with multimodal input, Speediance plans to deliver highly personalized fitness journeys, while the system records every action, tracks progress, and fine-tunes workouts based on real-time data. "Everyone believes AI will define the future, but the real question is: where can AI make the most impact?" says Liu Tao, CEO of Speediance. "We believe fitness is a perfect application. With large language models (LLM) continuously analyzing user data and our digital system recording every movement, we're creating a comprehensive ecosystem that not only tracks progress but evolves with the user. This is the next step in revolutionizing the health and wellness industry." Speediance's vision doesn't just stop at physical fitness. The company is looking to use AI to provide holistic lifestyle support, helping users achieve their best in both physical and mental well-being. By seamlessly integrating health monitoring and coaching, Speediance aims to be more than just a fitness tool—it will become a partner in users' overall wellness journeys. Catch Speediance at CES 2025 and discover how technology can turn resolutions into results. This isn't just fitness—it's a revolution in health and lifestyle.
Exhibition dates: January 7th - January 10th, Booth Number: Halls D #55532 at The Venetian Expo, 201 Sands Ave, Las Vegas, Nevada.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
This Tech at CES 2025 Might Make Your New Year's Resolution a Reality
BEIJING, Jan. 9, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced algorithms, physics simulations, and high-throughput experimentation to rapidly develop potential drug candidates for challenging targets. The platform's success with β-catenin, a key player in cancer development, demonstrates its potential to revolutionize drug discovery for previously intractable targets.
The Wnt/β-catenin pathway plays a crucial role in various biological functions and is implicated in multiple cancers[1-3]. Despite its importance as a therapeutic target[4-7], β-catenin has long been considered "undruggable" due to its flat protein surface[8-10]. The RiDYMO® platform overcomes this challenge by leveraging a vast library of over 10^12 cyclic peptides and macrocyclic molecules, incorporating both natural and non-natural amino acids.
Using the RiDYMO® platform, researchers rapidly designed and screened cyclic peptide molecules for β-catenin binding. The process involved:
The results were impressive, with 12 compounds showing strong inhibition of protein-protein interactions (IC50≤10 μM), a success rate of over 40%. One standout compound, designated as compound 24, effectively bound to β-catenin, disrupted its interaction with BCL9, and inhibited the Wnt/β-catenin signaling pathway.
Dr. Dongdong Wang, Co-President of DP Technology's Drug Discovery Unit, emphasized the platform's ability to tackle undruggable targets and rapidly design high-quality compounds. The RiDYMO® platform's success with β-catenin demonstrates its potential to accelerate the development of orally available cyclic peptide drugs, potentially transforming the pharmaceutical industry's approach to challenging targets.
This breakthrough in cyclic peptide design for β-catenin showcases the power of AI-driven drug discovery platforms in addressing previously intractable targets, potentially opening new avenues for cancer treatment and other therapeutic areas.
About the RiDYMO® Hit Discovery and Optimization Platform
RiDYMO® is a state-of-the-art hit discovery and optimization platform developed by DP Technology, leveraging the principles of AI for Science. It employs the proprietary Hermite® computational drug design software to elucidate the dynamics of "undruggable" targets and explores a broader chemical space encompassing small molecules, macrocycles, and cyclic peptides. By integrating advanced artificial intelligence, physics-based algorithms, and high-throughput experimentation, the platform excels in designing oral macrocyclic compounds and rapidly delivers innovative drug candidates.
As one of its core algorithms, Reinforced Dynamics (RiD)[4] has a significant advantage in the sampling efficiency of molecular dynamics simulation. By fully leveraging the high-dimensional representation capabilities of neural networks, RiD can efficiently capture dynamic conformational changes in complicated biomolecular systems. Previously, the core RiD algorithm of the platform was published in Nature Computational Science [11]. The study demonstrated that RiD could achieve a more comprehensive free energy surface within 1.86 μs, compared to 100 μs required by traditional MD methods, representing nearly a hundredfold increase in efficiency.
RiDYMO® has been successfully employed in various drug discovery programs, including the development of small molecule compounds for crucial targets such as c-Myc and GPX4, as well as other modalities such as cyclic peptides and ADCs.
For more information, please visit our website.
(https://www.dp.tech/en/services/medicine).
About Hermite
Hermite® is a next-generation computational drug design platform developed by DP Technology, powered by AI for Science, to provide a comprehensive solution for drug design. Hermite® integrates industry-leading tools such as the Free Energy Perturbation module ("Uni-FEP"), and the ultra-high-throughput virtual screening tool ("Uni-VSW"). The platform supports key stages of drug discovery from protein structure prediction and target validation to hit discovery and lead optimization.
In addition, the platform offers an interactive, web-based molecular visualization experience, with detailed management of projects, teams, and data. It features full compliance certification, multi-tier security measures. Users have the flexibility to choose between cloud-based or private deployment options.
Hermite® is rapidly gaining traction in the pharmaceutical industry, with over 60% of leading companies in China utilizing the platform across more than 50 drug pipelines. This growing trust is reflected in the impressive number of calculations performed—over 200,000 Uni-FEP calculations to date—demonstrating Hermite®'s reliability and effectiveness as a powerful tool for drug discovery and development.
For more information, please visit: https://www.dp.tech/en/product/hermite
References:
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
